Verve Therapeutics (VERV) Projected to Post Quarterly Earnings on Tuesday

Verve Therapeutics (NASDAQ:VERV) is projected to announce its earnings results before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of ($0.72) per share for the quarter.

Verve Therapeutics Stock Performance

Shares of NASDAQ:VERV opened at $7.28 on Friday. The company’s 50-day moving average is $6.80 and its 200 day moving average is $5.96. The company has a market capitalization of $616.32 million, a P/E ratio of -2.96 and a beta of 1.74. Verve Therapeutics has a fifty-two week low of $4.30 and a fifty-two week high of $19.34.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on VERV shares. Royal Bank of Canada cut their price target on shares of Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Canaccord Genuity Group boosted their price target on shares of Verve Therapeutics from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. William Blair reissued an “outperform” rating on shares of Verve Therapeutics in a report on Friday. Finally, HC Wainwright cut their price target on shares of Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $25.75.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.